Skip to Main Content

TherapeuticsMD met with FDA officials one month ago but is still waiting for a resolution to the agency’s rejection of its estrogen therapy for postmenopausal women known as TX-004HR. The “regulatory update” announced Monday with no clear plan forward was not well received by investors. TherapeuticsMD shares are down 11 percent.

TX-004HR is a capsule filled with estradiol (bioidentical estrogen) that menopausal women insert into their vaginas to deal with the bothersome vaginal changes — dryness, itching, pain during sex — that can occur when the body’s own estrogen levels fall.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

Comments are closed.